Protara Therapeutics (Protara Therapeutics) Cash-to-Debt : 10.57 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Protara Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 10.57.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Protara Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Protara Therapeutics's Cash-to-Debt or its related term are showing as below:

TARA' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.57 Med: 14.25 Max: No Debt
Current: 10.57

During the past 6 years, Protara Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 10.57. And the median was 14.25.

TARA's Cash-to-Debt is ranked better than
57.13% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs TARA: 10.57

Protara Therapeutics Cash-to-Debt Historical Data

The historical data trend for Protara Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Protara Therapeutics Cash-to-Debt Chart

Protara Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

155.10

12.60

13.22

12.00

Protara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															14.06	13.55	12.98	12.00	10.57

Competitive Comparison of Protara Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Protara Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protara Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Cash-to-Debt falls into.

Protara Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Protara Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	65.58	/	(0.983	+	4.484)
	=	12.00

Protara Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	55.223	/	(1	+	4.227)
	=	10.56

Protara Therapeutics (NAS:TARA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Protara Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics (Protara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

1KPA:Germany 1KPA:Germany

Address

345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010

Website

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Executives

Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Jesse Shefferman	director, officer: CEO and President	C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry	officer: VP, Controller	345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari	officer: Chief Medical Officer	C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang	director	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo	officer: Chief Medical Officer	C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall	10 percent owner	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly	director	ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy	officer: Chief Medical Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo	officer: Sr. Vice President, Research	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014